Beta Products Policy

Last Revision: Feb 2025

This Beta Product Policy (“Policy”) sets forth the terms and conditions under which MedMe (“Company”, “we”, “us”, or “our”) makes available pre-release software products (“Beta Products”) to select customers (“Participants” or “you”) for testing, evaluation, and feedback purposes. By using our products in Beta, you agree to comply with the terms of this Policy, in addition to any applicable service agreements.

1. Purpose and Scope
1.1 Purpose.
The purpose of this Policy is to establish clear guidelines for your participation in our Beta Program. The objectives are to:
- Enable you to test and evaluate Beta Products.
- Gather valuable feedback to improve our products.
- Inform you of the inherent risks and responsibilities associated with using experimental software.
1.2 Scope.
This Policy applies to all Beta Products offered by MedMe, including but not limited to products like AI Scribe and any future beta offerings.

2. Definitions
2.1 Beta Product.
Any pre-release version of software or service provided by MedMe for testing and evaluation purposes.
‍
2.2 Beta Program.
The program under which Beta Products are made available to Participants for the purpose of testing, providing feedback, and helping MedMe improve its products.
‍
2.3 Feedback.
Any information, suggestions, recommendations, or other communications provided by you related to the performance, functionality, or usability of a Beta Product.

3. Beta Participation and Feedback
3.1 Active Participation.
As a Participant in the Beta Program, you agree to actively engage with MedMe by:
‍Participating in scheduled feedback sessions, surveys, or calls.
-Providing timely and constructive feedback on any aspect of the Beta Product, including bugs, errors, usability issues, and potential enhancements.
‍
3.2 Feedback Ownership.
All Feedback provided by you will become the sole property of MedMe. By submitting Feedback, you grant MedMe a worldwide, irrevocable, royalty-free license to use, modify, reproduce, and incorporate such Feedback into its products without further compensation.

4. Monitoring, Data Collection, and Use
4.1 Usage Monitoring Consent.
By participating in the Beta Program, you consent to MedMe installing third-party analytics tools (e.g., Hotjar, Mouseflow) on your systems. These tools will monitor product usage—including tracking user interactions and session recordings—for the sole purpose of analyzing usage patterns and improving the Beta Product.

4.2 Recording and Quality Assurance.
MedMe may record user sessions, capture transcripts, and collect other data during your use of the Beta Product to perform quality assurance and product development activities. These recordings and data may be stored, reviewed, and aggregated in de-identified form.

4.3 PHI Redaction Disclaimer.
While MedMe employs automated mechanisms to redact Protected Health Information (PHI) during recordings, you acknowledge that such redaction features may not be perfect. You accept the residual risk that PHI might inadvertently be captured, and MedMe will not be held liable for any such exposure.

5. Beta Product “As-Is” and Warranty Disclaimers
5.1 As-Is Provision.
Beta Products are provided “as is” without any warranty, express or implied, including any implied warranties of merchantability, fitness for a particular purpose, or non-infringement. You acknowledge that Beta Products are experimental and may contain errors or defects.

5.2 Limitation of Liability.
In no event shall MedMe be liable for any direct, indirect, incidental, consequential, special, or punitive damages arising from or related to your use of a Beta Product. Your use of any Beta Product is entirely at your own risk.

6. Data Retention, Security, and Confidentiality
6.1 Data Retention.
MedMe may retain all data, recordings, transcripts, and Feedback collected during the Beta Program for a reasonable period to support product development, quality assurance, and compliance with legal obligations.

6.2 Confidentiality.
All data collected as part of the Beta Program—including usage data and session recordings—will be treated as confidential. MedMe will use such information solely for the purposes described in this Policy and in accordance with applicable privacy laws.

6.3 Your Responsibility.
You are responsible for ensuring that any sensitive information on your end is managed in accordance with your internal security policies. You should take appropriate steps to secure your systems and ensure compliance with applicable laws regarding PHI and other sensitive data.

7. Participant Responsibilities
7.1 Compliance with Policy.
By participating in the Beta Program, you agree to comply with this Policy and all instructions provided by MedMe regarding the use of Beta Products.

7.2 Reporting Issues.
You agree to promptly report any bugs, errors, or security issues you encounter while using a Beta Product. This reporting is essential for MedMe to improve the final product.

7.3 Data Backup.
You acknowledge that Beta Products may cause data loss or corruption. It is your responsibility to back up all important data before participating in the Beta Program.

8. Term and Termination
8.1 Term.
This Policy governs your participation in the Beta Program for as long as you use any Beta Product provided by MedMe.

8.2 Termination.
Either party may terminate your participation in the Beta Program at any time by providing written notice. Upon termination, you agree to cease using the Beta Product and, if applicable, to securely delete or return any materials provided by MedMe.

8.3 Survival.
Sections regarding data collection, confidentiality, liability, indemnification, and governing law shall survive termination of this Policy.

9. Indemnification
You agree to indemnify, defend, and hold harmless MedMe, its affiliates, officers, employees, and agents from and against any claims, losses, damages, liabilities, and expenses (including reasonable attorney fees) arising from your breach of this Policy or your use of any Beta Product.

10. Governing Law and Dispute Resolution
10.1 Governing Law.
This Policy shall be governed by and construed in accordance with the laws of the Province of [Insert Province], Canada, and applicable federal laws.

10.2 Dispute Resolution.
Any disputes arising out of or related to this Policy shall be resolved through binding arbitration in accordance with the rules of Ontario. Each party agrees that arbitration shall be the exclusive remedy for such disputes.

11. Modification of the Policy
MedMe reserves the right to modify or update this Policy at any time. Any changes will be communicated to Participants via email or through our platform. Continued participation in the Beta Program after any modifications constitutes your acceptance of the revised terms.

12. Miscellaneous
12.1 Entire Agreement.
This Policy constitutes the entire agreement regarding your participation in the Beta Program and supersedes all prior communications or understandings regarding Beta Products.

12.2 No Waiver.
The failure of MedMe to enforce any provision of this Policy shall not constitute a waiver of its right to enforce such provision at a later time.

12.3 Severability.
If any provision of this Policy is found to be invalid or unenforceable, the remaining provisions shall continue in full force and effect.